Several other phase I trials confirmed the efficacy of ABT-263, but patients exhibited signs of thrombocytopenia and T-cell lymphopenia due to the inhibition of BCL-XL and BCL-2, respectively [50–52]. The gene discussed is BCL2; the disease is Thrombocytopenia.